Law360, New York (October 03, 2012, 8:17 PM ET) -- A major generic pharmaceutical industry group on Monday urged the U.S. Supreme Court to grant Upsher-Smith Laboratories Inc.'s bid for review of a Third Circuit ruling that pay-for-delay pharmaceutical patent settlements are presumptively anti-competitive.
The Generic Pharmaceutical Association lodged an amicus brief in support of Upsher-Smith's petition for certiorari in a dispute over settlements relating to patents for Merck & Co. Inc.'s blood pressure medication K-Dur 20. The petition is one of two pending before the high court over the Third Circuit's ruling that such settlements...
Generics Group Urges High Court To Take Pay-For-Delay Case
To view the full article, take a free trial now.
